Trends in the use of primary prophylactic colony-stimulating factors and neutropenia-related hospitalization in elderly cancer patients receiving myelosuppressive chemotherapy in the USA: 1995

Trends in the use of primary prophylactic colony-stimulating factors and neutropenia-related hospitalization in elderly cancer patients receiving myelosuppressive chemotherapy in the USA: 1995–2015

Published:2019-10-17 Issue:6 Volume:28 Page:2637-2649
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Li Shuling,Liu Jiannong,Guo Haifeng,Gawade Prasad L.,Kim Christopher,Bensink Mark E.,Chandler David

Funder

Amgen

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00520-019-05080-w.pdf

Reference40 articles.

1. Smith RE (2006) Trends in recommendations for myelosuppressive chemotherapy for the treatment of solid tumors. J Natl Compr Cancer Netw 4:649–658

2. Giordano SH, Lin YL, Kuo YF, Hortobagyi GN, Goodwin JS (2012) Decline in the use of anthracyclines for breast cancer. J Clin Oncol 30:2232–2239

3. Marquart J, Chen EY, Prasad V (2018) Estimation of the percentage of us patients with cancer who benefit from genome-driven oncology. JAMA Oncol 4:1093–1098

4. Crawford J, Dale DC, Kuderer NM, Culakova E, Poniewierski MS, Wolff D, Lyman GH (2008) Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Cancer Netw 6:109–118

5. Lyman GH, Kuderer NM (2003) Epidemiology of febrile neutropenia. Support Cancer Ther 1:23–35

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Impact of Prophylactic Growth Factor Use on Timing of Febrile Neutropenia and Infection After High-Risk Chemotherapy;Journal of the National Comprehensive Cancer Network;2023-09

2. Impact of primary prophylaxis by pegfilgrastim in diffuse large B-cell lymphoma treated with R-CHOP;Annals of Hematology;2023-08-21

3. Two decades of pegfilgrastim: what have we learned? Where do we go from here?;Current Medical Research and Opinion;2023-04-08

4. Effectiveness and Safety of Filgrastim (Neupogen™) versus Filgrastim-aafi (Nivestim™) in Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia: An Observational Cohort Study;Drugs - Real World Outcomes;2022-09-07

5. G-CSF primary prophylaxis use and outcomes in patients receiving chemotherapy at intermediate risk for febrile neutropenia: a scoping review;Expert Review of Hematology;2022-07-03